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Key Points 26 
      27 
Question Does a dose of a daily oral probiotic combination of Lactobacillus rhamnosus GG 28 
and Bifidobacterium animalis subsp. lactis BB-12 reduce cumulative systemic antibiotic 29 
administration days for all-cause, acute infections in care home residents?            30 
 31 
Findings In this randomized clinical trial that included 310 participants, this daily probiotic 32 
combination, compared with placebo, did not significantly reduce antibiotic administration 33 
over 1 year (mean cumulative antibiotic administration days, 12.9 days vs 12.0 days). 34 
      35 
Meaning The findings do not support the use of probiotics for reducing antibiotic 36 
administration in older adults living in care homes 37 
 38 
 39 
 40 
 41 
 42 
 43 
44 
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Abstract 45 
IMPORTANCE Probiotics are frequently used by residents in care homes (residential 46 
homes or nursing homes that provide residents with 24-hour support for personal care or 47 
nursing care), although the evidence on whether probiotics prevent infections and reduce 48 
antibiotic use in these settings is limited. 49 
 50 
OBJECTIVE To determine whether a daily oral probiotic combination of Lactobacillus 51 
rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12 compared to placebo 52 
reduces antibiotic administration in care home residents.  53 
 54 
DESIGN, SETTING, AND PARTICIPANTS Placebo-controlled randomized trial of 310 55 
care home residents aged 65 years and older recruited from 23 care homes in the UK between 56 
December 2016 and May 2018, with last follow up on 31st October 2018.  57 
 58 
INTERVENTIONS Study participants were assigned to receive a daily capsule containing a 59 
probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. 60 
lactis BB-12 (total cell count per capsule 1.3x1010 - 1.6x1010) (n=155), or daily matched 61 
placebo (n=155), for up to one year.  62 
 63 
MAIN OUTCOME MEASURE The primary outcome was cumulative antibiotic 64 
administration days for all cause infections measured from randomization for up to one year. 65 
 66 
RESULTS Among 310 randomized care home residents (mean age 85.3 years; 66.8% 67 
women), 195 (62.9%) remained alive and completed the trial. Participant diary data (daily 68 
data including study product use, antibiotic administration, and signs of infection) were 69 
available for 97.4% randomized to placebo and 98.7% randomized to the probiotic group. 70 
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Care home residents randomized to the probiotic group had a mean cumulative systemic 71 
antibiotic administration days of 12.9 days (95% CI: 0 to 18.05), and those randomized to 72 
placebo, 12.0 days (95% CI: 0 to 16.95) (absolute difference = 0.9 days, 95% CI: -3.25 to 73 
5.05 days; adjusted incidence rate ratio = 1.13, 95% CI: 0.79 to 1.63, P=.50).  A total of 120 74 
care home residents experienced 283 adverse events, including 78 (58.6%) 75 
hospitalizations in the placebo group and 94 (62.7%) in probiotic group. There were 32 76 
deaths (20.6%) in the placebo group and 33 (21.3%) in the probiotic group. 77 
. 78 
CONCLUSIONS AND RELEVANCE Among care home residents in the UK, a daily dose 79 
of a probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis 80 
subsp. lactis BB-12 did not significantly reduce antibiotic administration for all-cause 81 
infections. These findings do not support the use of probiotics in this setting. 82 
 83 
TRIAL REGISTRATION The trial is registered with the ISRCTN, Registry number 84 
ISRCTN16392920. 85 
 86 
87 
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Background 88 
Global sales of probiotics are estimated at over $40 billion and are projected to reach over 89 
$64 billion by 2023.1 The US hospital and nursing home market for probiotics was estimated 90 
at $92.4 million in 2016, and is projected to expand at an estimated compound annual growth 91 
rate of 9.3% from 2017 to 2025.2 Probiotics are often promoted for health indications3 and 92 
may be an inexpensive and safe intervention to reduce antibiotic use and resistance through 93 
preventing infections.4 5 94 
 95 
A systematic review of probiotics to reduce antibiotic use for common infections in infants 96 
and children included 17 RCTs that evaluated 13 probiotic formulations of Lactobacillus and 97 
Bifidobacterium strains singly or combined, and found that probiotic use was associated with 98 
reduced risk of antibiotic prescription relative to placebo.6 A further systematic review of 20 99 
RCTs in otherwise healthy children and adults found that use of  Lactobacillus and 100 
Bifidobacterium probiotic strains was associated with reduced duration of respiratory illness 101 
in children.7 However, the quality of this supporting evidence was variable, and the authors 102 
called for additional well-designed studies to substantiate the findings and explore effects in 103 
other population groups.6,7 104 
 105 
With the aging population, care homes are an increasingly important care sector; care home 106 
residents are more prone to infections and consume more antibiotics than the general 107 
population,8 increasing the risk of antimicrobial resistance and poor outcomes.9 The 108 
Probiotics to reduce infections in care home residents(PRINCESS) trial was designed to test 109 
the hypothesis that daily administration of a combination of Lactobacillus rhamnosus GG  110 
and Bifidobacterium animalis subsp. Lactis BB-12 probiotics to care home residents would 111 
reduce cumulative systemic antibiotic administration days for all-cause, acute infections. 112 
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Methods 113 
Trial Design 114 
This study was designed as a multicenter, parallel, individually randomized, placebo 115 
controlled, double-blind clinical trial, and was conducted between December 2016 and May 116 
2018 in UK care homes. The trial was approved by the Research Ethics Committee (REC) for 117 
Wales (Wales REC 6) recognized by the UK Ethics Committee Authority (14/WA/1106), 118 
which approved all recruitment sites. National Health Service (NHS) Health Boards and 119 
Clinical Commissioning Groups gave Research and Development approval to sites. Informed, 120 
written consent was obtained from those participants with capacity to do so, and for those 121 
who lacked capacity to provide consent, a consultee (either a legal representative or guardian) 122 
could complete a consultee declaration for participation on their behalf. The protocol has 123 
been published,10 and the final protocol, amendments, and statistical analysis plan are 124 
available in Supplement 1.      125 
 126 
Participants 127 
Care home residents in this trial included those living in residential, nursing, and dual 128 
registered homes. Care home residents were eligible if they were aged 65 years or older. 129 
Exclusions were being immunocompromised (ongoing immune-suppressants; long-term, 130 
high-dose, oral, intramuscular or intravenous steroids), or taking ongoing, regular probiotics. 131 
Full eligibility criteria are provided in eAppendixes 1 of Supplement 2.  132 
 133 
Treatment allocation 134 
Participants were randomized using an online process in a 1:1 ratio using minimization to 135 
balance groups by care home and resident sex, with a random component set at 80%.  136 
 137 
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Procedures 138 
Nurses registered with the UK Nursing and Midwifery Council, blind to group allocation, 139 
visited each care home each week, and recorded weekly diary data for each participant in an 140 
online database, including the amount of study product (probiotic or placebo) taken each day; 141 
signs of infection; use of antibiotics including route; diarrhea; hospitalization; and serious or 142 
trial-related adverse events. Data were obtained from participants’ daily medical 143 
administration records, care home clinical records, observation of the participant, discussion 144 
with the participant or their friends and family, care home staff, and hospital discharge 145 
summaries. EQ-5D (health utility) and ICEpop CAPability measure for Older people 146 
(ICECAP-O) (wellbeing) questionnaires were collected at baseline, a 3-month follow-up 147 
point and a follow-up point as close to 12-months as the study would allow (some participant 148 
follow-up was truncated). Participants were asked to provide stool and saliva samples at 149 
baseline, 3-months, and up to 12-months, but this was not a requirement for participation.  150 
 151 
Interventions 152 
Participants were allocated a daily oral probiotic combination of Lactobacillus rhamnosus 153 
GG and Bifidobacterium animalis subsp. lactis BB-12 (total cell count per capsule of between 154 
1.3x1010 to 1.6x1010), or a matched placebo (containing maltodextrin, microcrystalline 155 
cellulose, magnesium stearate, and silicon dioxide), as a capsule once daily while the care 156 
home resident remained in the study (see eAppendixes 2 of the Supplement). The study 157 
product was not administered while care home residents were away from care homes such as 158 
when hospitalized, after withdrawal from the study. 159 
 160 
Outcomes  161 
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The primary outcome was cumulative systemic antibiotic administration days for all cause 162 
infections, defined as the total number of days of systemic antibiotic administration as 163 
recorded in care home medical records and hospital discharge summaries and with the 164 
denominator calculated as the total number of days participants were observed in the study.  165 
 166 
Secondary outcomes included: total number of days of antibiotic administration for each 167 
infection category recorded in care home medical records (urinary tract infection, 168 
gastrointestinal infection, respiratory tract infections (divided into upper and lower 169 
respiratory tract infections post hoc after the Trial Management Group decided it would be 170 
more informative to evaluate these outcomes separately), skin and soft tissue infection, 171 
unexplained fever, and other); number, site, duration (mean and cumulative) of infection; 172 
duration of diarrhea when  oral antibiotics were taken and not taken,; antibiotic-associated 173 
diarrhea; incidence of Clostridioides difficile infection; antibiotic sensitivity of stool Gram-174 
negative Enterobacteriaceae and vancomycin resistant enterococci (VRE), and counts of  175 
Lactobacillus rhamnosus and Bifidobacterium animalis subsp. Lactis; oral Candida spp; self-176 
and/or proxy reported health-related quality of life measured by EQ-5D-5L (index value 177 
range from -0.594 (worst) to 1 (best); health status range from 0 (worst) to 100 (best)) and 178 
ICECAP-O (range from 0 (worst) to 1 (best));11 number and duration of hospital stays, and; 179 
deaths. eAppendix 3 of Supplement 2 provides further details on the derivation of some 180 
outcomes.  181 
 182 
Statistical analyses 183 
An estimated 330 participants from 20 UK care homes would provide 90% power at the 5% 184 
level to demonstrate a 10% relative reduction in cumulative systemic antibiotic 185 
administration days, assuming a mean cumulative systemic antibiotic administration days of 186 
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17.4 days and a 10% reduction in the probiotic group to 15.6 days per resident-year.8 We 187 
considered a 10% reduction feasible and clinically important,12 because physician targeted 188 
interventions to reduce antibiotic use for respiratory tract infections have been associated 189 
with an average reduction in antibiotic prescriptions of 11.6%;13  longer duration of antibiotic 190 
exposure has been associated with increased risk of subsequent infections with drug-resistant 191 
organisms14; approximately 20% of all antibiotics prescribed in primary care in England are 192 
considered inappropriate,15  and the UK government initiative was to halve inappropriate 193 
prescribing, amounting to a 10% relative reduction.16 194 
This sample size accounted for 30% of participants contributing no outcome data (i.e. 195 
randomized but contributing to neither the numerator or denominator). Our target sample size 196 
was adjusted after a planned interim assessment of outcome data availability after 3 months 197 
(33 participants) to be at least 258. Assuming a mean number of days for which primary 198 
outcome data could be available (i.e. accounting for follow-up time) of approximately 250 199 
days, this would provide at least 82% power to detect a 10% relative reduction in cumulative 200 
systemic antibiotic administration days.  201 
 202 
Primary and secondary comparative analyses were pre-specified and included all randomized 203 
participants who provided outcome data, analyzed in the group to which they were 204 
randomized without imputation to account for loss of observation time. The mean cumulative 205 
systemic antibiotic administration days per resident-year was compared between groups by 206 
fitting a two-level negative binomial regression model, accounting for participants nested 207 
within care homes, the length of time observed, and the sex of care home residents. Similarly, 208 
the majority of secondary outcome analyses (cumulative systemic antibiotic administration 209 
days by infection type, rates of infections, rates of diarrhea) involved the between-group 210 
comparison of rate variables using two-level Poisson or negative binomial regression 211 
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(depending on the presence of over-dispersion). The decision to analyze lower and upper 212 
respiratory tract infections separately was made post hoc by the Trial Management Group 213 
because reporting lower respiratory tract infections separately was considered important, as 214 
these infections typically cause greater morbidity in the study population than upper 215 
respiratory infections. The consistency of conclusions drawn from the primary analysis was 216 
investigated by conducting the following pre-specified sensitivity analyses: i.) including 217 
prophylactic antibiotic use in the definition of cumulative systemic antibiotic administration 218 
days; ii.) ignoring periods of hospitalization from both the numerator and denominator; iii.) 219 
handling data truncated due to death from infection by imputing participants as having been 220 
administered antibiotics for the remainder of the time they should have been observed in the 221 
trial (a composite strategy)17; iv.) accounting for study product consumption (see eAppendix 222 
4 of Supplement 2). Because of the potential for type 1 error due to multiple comparisons, 223 
findings for analyses of secondary endpoints should be interpreted as exploratory. For all 224 
analyses, two-sided 95% confidence intervals and p-values were calculated. P-values <.05 225 
were considered statistically significant. Statistical analyses were conducted using IBM SPSS 226 
version 25 and STATA version 15. Further details of statistical analyses are provided in 227 
eAppendix 4 of Supplement 2. 228 
 229 
230 
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Results 231 
Participants 232 
310 care home residents, 155 in each group, were randomized from 23 care homes in the UK 233 
between December 2016 and May 2018. Due to slower than anticipated recruitment, follow-234 
up was truncated for 106 care home residents, with these care home residents followed-up for 235 
between 147 and 362 days in total. Among the 199 participants who remained alive, had 236 
not withdrawn from the study, and could have had a second follow up at 12-months 237 
post-randomization (or earlier for those whose follow-up was truncated), responses were 238 
available for 195 (98.0%) care home residents, 98 in the probiotic group and 97 in the 239 
placebo group (Figure 1). The mean age was 85.3 years (SD 7.39) years; 33.2% (103/310) 240 
were men and 66.8% (207/310) were women; 65.8% (204/310) lacked capacity to consent. 241 
Care home residents in trial groups were well matched for these and most other 242 
characteristics at baseline, including stool sample culture for probiotic organisms. However, 243 
more care home residents in the probiotic group had Clostridioides difficile cultured from 244 
their stool (6/83) compared to the placebo group (0/75) (Table 1). Care home residents 245 
allocated to the probiotic group contributed 39,798 person days (mean number of days per 246 
probiotic participant = 252.4, SD = 110.51) and care home residents allocated to placebo 247 
contributed 37,974 person days (mean days = 242.9, SD = 115.24). The primary cause of 248 
unobserved data was truncation due to death, with post-randomization deaths occurring in 33 249 
care home residents allocated to probiotic and 32 allocated to placebo (total number of 250 
unobserved days due to death = 7,578 and 6,978 respectively). Other reasons for unobserved 251 
data were care home residents being away from the care home (114 days in placebo group 252 
and 56 days in probiotic group), waiting for a capacity assessment (zero in placebo group and 253 
7 days in probiotic group), and data not collected for unknown reason (972 days in placebo 254 
group and 1898 in probiotic group). 305 (98.4%) care home residents contributed to the 255 
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primary analysis and secondary analyses relating to infections and diarrhea, with 5 care home 256 
residents excluded from these analyses due to death or withdrawal following randomization 257 
and prior to contributing data.  258 
 259 
Intervention fidelity 260 
302 (97.4%) care home residents initiated at least 1 dose of study product, 98.1% (152/155) 261 
in the placebo group and 96.8% (150/155) in the probiotic group. Of the remaining 8 care 262 
home residents, 5 withdrew following randomization and 3 died soon after randomization. 263 
For the 302 care home residents who initiated at least one study product dose, a median of 264 
97.8% (IQR 93.56 to 99.45) full or partial doses were taken, and 89.4% (65,525/77,772) were 265 
either swallowed as capsules, or sprinkled on food (that was not hot) prior to ingestion. 266 
 267 
Significantly more stool samples from care home residents randomized to probiotic were 268 
found to contain Lactobacillus rhamnosus than samples from those randomized to placebo at 269 
three-months post-randomization (47/56 – 83.9% versus 19/52 – 36.5%, absolute risk 270 
difference = -47.4%, 95% CI: -64.8 to -29.0%; AOR = 9.19, 95% CI: 3.51 to 24.07, P < 271 
.001), mean concentrations were 7.04 x 105 (SD = 3.05 x 106) for those randomized to 272 
probiotic and 4.67 x 104 (SD = 2.77 x 105) in placebo. This finding persisted at the second 273 
follow-up time point (27/37 – 73.0% versus 9/29 – 31.0%, absolute risk difference = -41.9%, 274 
95% CI: -66.1 to -17.7%; AOR = 6.41, 95% CI: 2.14 to 19.20, p = .001), mean 275 
concentrations 1.52 x 105 (SD = 5.27 x 105) in probiotic versus 1.40 x 104 (SD = 4.31 x 104) 276 
in the placebo group. 277 
 278 
Care home residents randomized to probiotic provided stool samples containing 279 
Bifidobacterium animalis subsp. Lactis significantly more frequently than those randomized 280 
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to placebo at 3 months (29/56 – 51.8% versus 2/52 – 3.8%, absolute risk difference = -47.9%, 281 
95% CI: -65.0 to -30.9%; AOR = 26.90, 95% CI: 5.94 to 121.66, p < .001), mean 282 
concentrations 1.72 x 106 (SD = 5.11 x 106) in the probiotic group and 2.88 x 104 (SD = 1.71 283 
x 105) in the placebo group. This finding persisted at the second follow-up time point (21/37 284 
– 56.8% versus 2/29 – 6.9%, absolute risk difference = -49.9%, 95% CI: -73.0 to -26.7%; 285 
AOR = 21.96, 95% CI: 2.97 to 162.43, p = .002) with mean concentrations 2.15 x 105 (SD = 286 
4.45 x 105) in the probiotic group versus 3.62 x 102 (SD = 1.86 x 103) in the placebo group.      287 
 288 
There were 202 (66.2%) care home residents who were prescribed at least one non-289 
prophylactic antibiotic, 69.1% (105/155) in the placebo group and 63.4% (97/155) in the 290 
probiotic group. 336 courses of non-prophylactic antibiotics were prescribed in the placebo 291 
group and 287 in the probiotic group. 292 
 293 
Primary outcome 294 
Care home residents randomized to probiotic had a mean cumulative systemic antibiotic 295 
administration days of 12.9 (95% CI: 0 to 18.05), and care home residents randomized to 296 
placebo had a mean cumulative systemic antibiotic administration days of 12.0 (95% CI: 0 to 297 
16.95). The distribution was positively skewed with 37% of residents having 0 days due to 298 
not being administered antibiotics (eFigure 1). The absolute difference in cumulative 299 
systemic antibiotic administration days was 0.9 days (95% CI, -3.25 to 5.05 days) and 300 
the adjusted incidence rate ratio (IRR) was 1.13 (95% CI, 0.79 to 1.63; P =.50).  Death 301 
due to infection was reported for 12 care home residents in the probiotic group and 6 in the 302 
placebo group, with 6 care home residents in the probiotic group and 1 in placebo group 303 
taken antibiotic up until death. Further details of sensitivity analyses for the primary outcome 304 
measure are provided in eTable 1 to eTable 3 of Supplement 2. 305 
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 306 
Secondary outcomes 307 
Care home residents allocated to a daily oral probiotic combination of Lactobacillus 308 
rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12 were administered 309 
significantly more antibiotics for lower respiratory tract infections than those randomized to 310 
placebo (mean 6.2 days in probiotic group compared to 4.0 days in placebo group; absolute 311 
difference = 2.2 days, 95% CI: -0.41 to 4.81 days; adjusted IRR=1.42, 95% CI: 1.05 to 1.93, 312 
P=.02). There was no statistically significant difference between groups in antibiotic use for 313 
urinary tract infections (mean 7.1 days  versus mean 6.7 days; absolute difference = 0.4 days, 314 
95% CI: -2.81 to 3.61 days; adjusted IRR = 1.17, 95% CI: 0.75 to 1.84, p =.48), upper 315 
respiratory tract infections (mean 3.3 days  versus mean 3.4 days; absolute difference = 0.1 316 
days, 95% CI: -2.09 to 2.29 days; adjusted IRR = 1.13, 95% CI: 0.71 to 1.78, P=.61), skin 317 
infections (mean 3.4 days versus mean 3.7 days; absolute difference = 0.3 days, 95% CI: -318 
2.20 to 2.80 days; adjusted IRR = 0.92, 95% CI 0.54 to 1.57, P=.76), and duration of 319 
infection (median 6 days  versus median 5 days; adjusted mean difference = 0.08, 95% CI -320 
0.001 to 0.16, P=.05) (see eFigure 2). Unexplained fever was not reported for any participants 321 
during the trial (Table 2). 322 
 323 
Care home residents allocated to the probiotic group had statistically significantly lower self-324 
reported generic wellbeing/capability scores at three months (mean score 0.72 versus mean 325 
score 0.69; absolute difference = 0.03, 95% CI: -0.05 to 0.11; adjusted mean difference= -326 
0.06, 95% CI: -0.11 to -0.001, P=.05). There were no statistically significant differences for 327 
other self-report and proxy wellbeing and quality of life outcomes (Table 3).  328 
 329 
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There was no statistically significant difference between groups in terms of care home 330 
residents being hospitalized at least once during the post-randomization study period (42/152 331 
– 27.6% in probiotic group versus 36/153 – 23.5% in placebo group; absolute risk difference 332 
= -4.1%, 95% CI: -13.9 to 5.7%; adjusted odds ratio = 1.25, 95% CI: 0.74 to 2.11, P=.41), 333 
number of hospital stays (mean 0.4  versus 0.3; absolute difference =  0.08, 95% CI: -0.06 to 334 
0.22; adjusted IRR = 1.17, 95% CI 0.72 to 1.90, P=.53), cumulative number of hospital days 335 
(mean 4.5 days  versus mean 5.4 days; absolute difference = 0.9 days, 95% CI: -2.77 to 4.57 336 
days; adjusted IRR = 1.00, 95% CI 0.43 to 2.29, P=1.00), or death (33/155 – 21.3% versus 337 
32/155 – 20.6%; absolute risk difference = -0.6%, 95% CI: -9.7 to 8.4%; adjusted odds ratio 338 
= 1.03, 95% CI 0.59 to 1.80, P=.90) (Table 3). Similarly, there was no statistically significant 339 
between-group differences for incidence of antibiotic-associated diarrhea (mean 0.8 versus 340 
mean 0.6; absolute difference = 0.2, 95% CI: -0.16 to 0.50; adjusted IRR = 1.39, 95% CI 0.79 341 
to 2.46, P=.25) and cumulative days of antibiotic-associated diarrhea (mean 6.8 days versus 342 
mean 4.4 days; absolute difference = 2.4 days, 95% CI: -2.00 to 6.71 days; adjusted IRR = 343 
1.83, 95% CI: 0.95 to 3.54, P=.07) (Table 3). 344 
 345 
There were no statistically significant differences between groups with regards to 346 
Enterobacterales resistant to at least 1 of the tested antibiotics in stool samples (3 months: 347 
37/55 – 67.3% in the probiotic group versus 39/52 – 75.0% in the placebo group; absolute 348 
risk difference = 7.7%, 95% CI: -9.5 to 25.9%; adjusted odds ratio 0.61, 95% CI 0.24 to 1.56, 349 
P=.30, second follow-up: 23/33 – 69.7% versus 19/27 – 70.0%; absolute risk difference = 350 
0.7%, 95% CI: -22.6 to 24.0%; adjusted odds ratio 0.76, 95% CI 0.20 to 2.89, P=.68), or in 351 
the presence of oral candida (3 months: 88/113 – 77.9% versus 80/105 – 76.2%; absolute risk 352 
difference = -0.2%, 95% CI: -11.3 to 10.9%; adjusted odds ratio 1.23, 95% CI 0.54 to 2.83, 353 
P=.62, second follow-up: 70/85 – 82.4% versus 57/76 – 75.0%; absolute risk difference = -354 
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7.4%, 95% CI: -20.0 to 5.3%; adjusted odds ratio 1.27, 95% CI 0.50 to 3.21, P=.62). Analysis 355 
of the outcome measures related to candidiasis are provided in eTable 4 of Supplement 2. 356 
Three stool samples were positive for vancomycin resistant enterococci at baseline, 3 month, 357 
and final follow-up time point. Further details of analysis of microbiology outcome measures 358 
are provided in eTable 5 of Supplement 2. 359 
 360 
At 3-months post-randomization, 7 of the 107 stool samples tested (6.5%) were positive for 361 
Clostridioides difficile, with a greater number detected in samples belonging to care home 362 
residents randomized to probiotic than placebo (6/55 10.9% versus 1/52 1.9%, absolute risk 363 
difference = -9.0%, 95% CI: -18.4 to 0.4%; AOR = 6.51, 95% CI: 0.75 to 56.57, p = .09). At 364 
the second follow-up, 2/64 samples tested (3.1%) yielded Clostridioides difficile. Both of 365 
these samples were from care home residents randomized to probiotic. 366 
 367 
Subgroup effects 368 
There were no statistically significant different intervention effects for any of the pre-369 
specified subgroups. Further details are provided in eTable 6 of Supplement 2. 370 
 371 
Adverse Events 372 
120 care home residents experienced 283 adverse events, including 78 (58.6%) 373 
hospitalizations in the placebo group and 94 (62.7%) in probiotic group, and 32 deaths 374 
(24.1%) in the placebo group and 33 (22.0%) in the probiotic group (Table 3). Three 375 
trial-related AEs were identified and all were in the placebo group; 1 stopped the study 376 
product because of choking risk, another because they reported the study product made their 377 
diarrhea worse, and another because the study product made them feel bloated.  378 
379 
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Discussion 380 
This double blind, placebo controlled clinical trial found that the administration of a daily 381 
dose of the probiotic combination, Lactobacillus rhamnosus GG and Bifidobacterium 382 
animalis subsp. lactis BB-12 to care home residents did not result in significantly fewer 383 
cumulative systemic antibiotic administration days for all-cause, acute infections.  384 
 385 
Prior studies of probiotics have produced contradictory findings and have been criticized for 386 
poor design, selective reporting, poorly described and verified outcomes, inadequate 387 
reporting of harms, and poor ascertainment of outcomes.3  In this trial, a registered nurse 388 
blind to randomization status visited study participants each week to complete participant 389 
diary data from multiple sources, with data for only 1.3% of eligible study days missing,, and 390 
probiotic organisms were identified more often and in greater counts in the stool of care 391 
home residents in the probiotic group.  392 
 393 
A recent meta-analysis on the effectiveness of probiotics in preventing infections in older 394 
adults included 15 studies covering 5,916 participants with mean age of 75.21 years.18 Three 395 
of the included studies recruited institutionalized older adults: Mane and colleagues 396 
randomized 50 participants to receive low, or high daily dose of Lactobacillus plamtarum or 397 
placebo for up to 12 weeks, and found that the high dose significantly increased the 398 
percentages of markers of immunogenicity, and significantly lowered incidence of 399 
infections.19 Van Puyenbroeck and colleagues randomized 737 nursing home residents to 400 
receive a fermented milk containing Lactobacillus casei Shirota or placebo for 176 days, and 401 
found no significant effect on the number of days with respiratory symptoms or anti-402 
influenza antibody titers after influenza vaccination.20 Nagata and colleagues randomized 72 403 
residents and staff members of facilities for older adults to receive Lactobacillus casei 404 
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Shirota in fermented milk or placebo each day for six months, and found a lower incidence of 405 
fever and improved bowel movements in those taking the probiotic.21  The authors of the 406 
review concluded that the overall quality of evidence was poor, and that it did not support the 407 
use of probiotics for reducing infections in older adults, that safety outcomes were similar 408 
between probiotics and placebo, and that more research was needed.18 409 
 410 
A subsequent, double blind, placebo controlled pilot trial of Lactobacillus rhamnosus GG or 411 
placebo daily for 6 months to prevent respiratory infections in 209 nursing home residents 412 
identified laboratory-confirmed respiratory viral infections in 14 (15.0%) and 21 (22.9%) in 413 
the placebo and probiotic groups respectively, and called for a larger trial.5  414 
 415 
A large trial of hospitalized patients found no benefit from short term lactobacilli and 416 
bifidobacteria with regard to antibiotic associated diarrhea,22 which conflicted with findings 417 
from several systematic reviews.23  418 
 419 
This trial found no beneficial effect of probiotic use compared with placebo on antibiotic use 420 
overall, or for the main categories of infections that commonly affect the population studied, 421 
duration of infections, health utility and wellbeing, hospitalizations, death, antibiotic-422 
associated diarrhea, or carriage of antibiotic resistant stool organisms. However, participants 423 
who were randomized to the probiotic group were administered significantly more antibiotics 424 
for lower respiratory tract infections, had a small but statistically significant lower self-425 
reported generic wellbeing/capability scores at 3 months, and a pre-specified sensitivity 426 
analysis found a significant increase in cumulative systemic antibiotic days. These findings 427 
should be interpreted with caution, given multiple testing. However, this study does not rule 428 
out harm from probiotics. Certain probiotics may delay the return of the host gut microbiome 429 
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to its normal state after antibiotic treatment,24 and a retrospective, single center study found 430 
probiotic exposure was associated with Clostridioides difficile infection in hospitalized 431 
patients.25 432 
 433 
Limitations  434 
This study has several limitations. First, although all care home residents remaining in the 435 
trial were followed up for at least 6 months, some had their follow-up truncated before the 436 
originally planned twelve months due to longer than expected study set-up. Second, a higher 437 
than expected proportion of stool cultures were positive for the study probiotics at baseline, 438 
and probiotic organisms were isolated from some of the stool samples obtained from the 439 
placebo group at follow-up, albeit at low counts. More sensitive microbiological techniques 440 
may partially explain isolation of these organisms at low counts, Exposure to the probiotic 441 
organisms in the placebo group would dilute any between-group differences in outcomes. 442 
Third, infection related outcomes were not based on standard definitions, as presentation of 443 
infections in this population is often non-specific, and care home residents were not tested for 444 
etiology using microbiological sampling. This may limit generalizability of some secondary 445 
outcomes. Fourth, given a lower than expected event rate, this study was underpowered to 446 
detect statistical significance for the minimal clinically important difference in the primary 447 
outcome. Fifth, these findings are not necessarily generalizable to other probiotics or 448 
probiotic combinations, or applicable to other populations, since the effects of probiotic 449 
supplementation may be strain specific and vary according to setting, immune status, and age.  450 
 451 
Conclusion 452 
Among care home residents in the UK, a daily oral probiotic combination of Lactobacillus 453 
rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12 did not significantly reduce 454 
20 
 
antibiotic administration for all-cause infections. The findings do not support the use of 455 
probiotics in this setting. 456 
 457 
458 
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Figure 1: Enrollment, randomization, and follow-up 667 
 668 
 669 
 670 
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Table 1: Participant characteristics at baseline  672 
Characteristic Probiotic (N=155*) Placebo (N=155*) 
Age, mean (SD), year 85.1 (7.6) 85.6 (7.21) 
Sex, n (%)     
  Male 52 (33.5) 51 (32.9) 
  Female 103 (66.5) 104 (67.1) 
  Lacks mental capacity to consent†, n (%) 98 (63.2) 106 (68.4) 
  Has mental capacity to consent†, n (%) 57 (36.8) 49 (31.6) 
Duration of residency in care home, 
median (IQR) N, year 1 (0, 2) 153 1 (0, 3) 154 
Height, mean (SD) N, cm 162 (7.8) 70 165 (8.8) 74 
Weight, median (IQR), kg 60 (52.1, 70.6) 63 (55.6, 72.9) 
Ulna length‡, mean (SD) N, cm 25 (2.5) 152 26 (2.5) 150 
Mid upper arm circumference§, mean (SD) 
N, cm 
27 (4.5) 151 27 (4.1) 150 
Clinical frailty scale||     
  Very fit to managing well 13 (8.4) 18 (11.6) 
  Vulnerable to moderately frail 64 (41.3) 51 (32.9) 
  Severely frail to terminally ill 78 (50.3) 86 (55.5) 
30 
 
Characteristic Probiotic (N=155*) Placebo (N=155*) 
Prescribed antimicrobials in the last four 
weeks, n (%) 45 (29.0) 37 (23.9) 
Used a proton pump inhibitor in the last 
four weeks, n (%) 61 (39.4) 52 (33.5) 
Used a laxative in the last four weeks, n 
(%) 75 (48.4) 85 (54.8) 
Used Vitamin D in the last four weeks, n 
(%) 50 (32.3) 44 (28.4) 
Stool sample - Lactobacillus rhamnosus  
growth on plate, n/N (%) 28/83 (33.7) 19/75 (25.3) 
Stool sample - Bifidobacterium animalis 
subsp. lactis growth on plate, n/N (%) 3/83 (3.6) 4/75 (5.3) 
Stool sample – Growth of Clostridioides 
difficile, n/N (%) 
6/83 (7.2) 
0/75 (0.0) 
*Unless otherwise specified. 673 
†If participants lacked capacity to consent, a consultee advised about their participation in 674 
accordance with the governing legislation 675 
‡Measure between the point of the elbow and the midpoint of the prominent bone of the 676 
wrist. 677 
§Measure the distance between the bony protrusion on the shoulder and the point of the 678 
elbow, mark the midpoint and measure around the arm at this point. 679 
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||Clinical frailty scale assesses the level of fitness or frailty of older adult, scores range from 680 
1 to 8: (1-3) very fit to managing well, (4-6) vulnerable to moderately frail, and (7-8) severely 681 
frail to terminally ill. 682 
  683 
 684 
 685 
 686 
687 
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Table 2: Between-group differences for infection-related outcome measures* 688 
 689 
Analysis  
Probiotic 
(n=155) 
Placebo 
(n=155) 
Absolute 
difference, 
95% CI 
Adjusted 
incidence 
rate ratio, 
95% CI p-value 
   
   
Primary outcome No. (%) 
with data 
152 
(98.1) 
153 
(98.7) 
          
Cumulative antibiotic 
administration days, mean 
(SD) 
12.9 
(18.4) 
12.0 
(18.6) 
0.9 (-3.3 to 
5.1) 
1.1 (0.8 to 
1.6) 
.50    
Secondary outcome No. 
(%) with data* 
152 
(98.1) 
153 
(98.7) 
          
Cumulative systemic 
antibiotic administration 
days for urinary tract 
infection†, mean (SD) 
7.1 (15.0) 6.7 
(13.6) 
0.4 (-2.8 to 
3.6) 
1.2 (0.8 to 
1.8) 
.48    
Cumulative systemic 
antibiotic administration 
days for upper respiratory 
tract infections, mean 
(SD) 
3.3 (9.4) 3.4 
(10.1) 
0.1 (-2.1 to 
2.3) 
1.1 (0.7 to 
1.8) 
.61    
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Analysis  Probiotic 
(n=155) 
Placebo 
(n=155) 
Absolute 
difference, 
95% CI 
Adjusted 
incidence 
rate ratio, 
95% CI 
p-value 
   
Cumulative systemic 
antibiotic administration 
days for lower respiratory 
tract infections, mean 
(SD) 
6.2 (14.6) 4.0 (7.6) 2.2 (-0.4 to 
4.8) 
1.4 (1.1 to 
1.9) 
.02    
Cumulative systemic 
antibiotic administration 
days for skin infections, 
mean (SD) 
3.4 (8.7) 3.7 
(13.1) 
0.3 (-2.2 to 
2.8) 
0.9 (0.5 to 
1.6) 
.76    
Incidence of any 
infection, mean (SD) 
2.5 (2.5) 2.4 (2.7) 0.1 (-1.3 to 
1.5) 
1.0 (0.8 to 
1.2) 
.92    
Incidence of urinary tract 
infections, mean (SD) 
0.8 (1.4) 0.8 (1.4) 0 (-0.3 to 
0.3) 
1.1 (0.6 to 
2.1) 
.68    
Incidence of 
gastrointestinal 
infections, mean (SD) 
0.03 (0.2) 0.04 
(0.2) 
0 (0 to 0.1) 0.8 (0.2 to 
2.6) 
.68    
Incidence for upper 
respiratory tract 
infections, mean (SD) 
0.4 (0.8) 0.5 (0.9) 0.1 (-0.1 to 
0.3) 
0.8 (0.5 to 
1.2) 
.31    
Incidence for lower 0.6 (1.0) 0.5 (0.9) 0.1 (-0.1 to 1.2 (0.8 to .41    
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Analysis  Probiotic 
(n=155) 
Placebo 
(n=155) 
Absolute 
difference, 
95% CI 
Adjusted 
incidence 
rate ratio, 
95% CI 
p-value 
   
respiratory tract 
infections, mean (SD) 
0.3) 1.7) 
Incidence for skin 
infections, mean (SD) 
0.6 (1.2) 0.5 (1.1) 0.1 (-0.2 to 
0.4) 
1.2 (0.7 to 
2.0) 
.49    
At least one infection, n 
(%) 
111 
(73.0) 
102 
(66.7) 
0.1 (0 to 
0.2) 
1.4 (0.8 to 
2.4) ‡ 
.20    
Duration of infection for 
those with at least one 
infection§, median (IQR) 
N 
6 (4, 9) 
111 
5 (3, 7) 
102 
0.9 (-0.4 to 
2.2) 
0.1 (0 to 0.2) 
** 
.05    
Cumulative number of 
infection days per person-
year††, median (IQR) 
13 (0, 27) 8 (0, 25) 1 (-7.1 to 
9.1) 
1.1 (0.8 to 
1.5) 
.67    
*Cumulative systemic antibiotic administration days for gastrointestinal infection was not 690 
reported due to a small number of participants having gastrointestinal infection (two 691 
participants in probiotic group and zero in placebo group). 692 
†Cumulative infection-site specific antibiotic administration days were rate variables 693 
expressed per person year. The numerator was the number of days that an antibiotic was 694 
administered for a specific infection (as indicated in the care home medical records) and the 695 
denominator was the period of exposure days. 696 
‡ Adjusted odds ratio, 95% CI 697 
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§Duration of infection was calculated by dividing the number of infection days by the total 698 
number of infections. See eFigure 2  for the distribution. 699 
**Adjusted mean difference, 95% CI 700 
††Cumulative number of infection days was a rate variable expressed as infection days per 701 
person year, with the number of suspected infection days as the numerator over the period of 702 
exposure days. During weekly visits, Research Nurses would record whether care home 703 
residents displayed signs of infection (and if so what infection/s), following discussions with 704 
Care Home Staff. This was asked and recorded separately to whether a care home resident 705 
received an antibiotic on a given day. 706 
 707 
708 
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Table 3: Between-group differences for secondary outcome measures* 709 
 710 
Secondary Analysis Probiot
ic 
(n=155) 
Placebo 
(n=155) 
Absolute 
difference, 
95% CI 
Adjusted 
difference, 
95% CI† 
p-value 
3-months EQ-5D index 
value*‡ 
          
  Self-report, mean (SD) 
N 
0.6 (0.3) 
49 
0.6 (0.2) 
43 
0 (-0.1 to 
0.2) 
Mean: -0.1 (-
0.1 to 0) 
.13 
  Proxy, mean (SD) N 0.5 (0.3) 
130 
0.5 (0.3) 
129 
0 (-0.1 to 
0.1) 
Mean: 0 (-0.1 
to 0) 
.66 
3-months EQ-5D health 
status*§ 
         
  Self-report, mean (SD) 
N 
65 
(18.3) 
44 
65 (20.6) 
42 
0.1 (-8.1 to 
8.3) 
Mean: -0.3 (-
8.0 to 7.5) 
.95 
  Proxy, mean (SD) N 71 
(19.1) 
128 
70 (20.6) 
130 
0.4 (-4.4 to 
5.2) 
Mean: 0.4 (-
4.1 to 4.8) 
.87 
Second follow-up EQ-
5D index value*‡ 
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Secondary Analysis Probiot
ic 
(n=155) 
Placebo 
(n=155) 
Absolute 
difference, 
95% CI 
Adjusted 
difference, 
95% CI† 
p-value 
  Self-report, mean (SD) 
N 
0.6 (0.4) 
38 
0.6 (0.3) 
31 
0 (-0.2 to 
0.2) 
Mean: 0 (-0.1 
to 0.1) 
.92 
  Proxy, mean (SD) N 0.5 (0.3) 
97 
0.5 (0.3) 
95 
0 (0 to 0.1) Mean: 0 (-0.1 
to 0.1) 
.79 
Second follow-up EQ-
5D health status*§ 
         
  Self-report, mean (SD) 
N 
65 
(21.4) 
34 
66 (21.5) 
29 
0.5 (-10.1 
to 11.1) 
Mean: 24.4 (-
1267.9 to 
1316.6) ‖ 
.97 
  Proxy, mean (SD) N 65 
(21.8) 
98 
64 (21.0) 
96 
0.6 (-5.4 to 
6.6) 
Mean: 0.6 (-
4.9 to 6.2) 
.82 
3-months ICECAP-O 
value¶ 
         
  Self-report, mean (SD) 
N 
0.7 (0.2) 
47 
0.7 (0.2) 
40 
0 (-0.1 to 
0.1) 
Mean: -0.1 (-
0.1 to -0) 
.05 
  Proxy, mean (SD) N 0.7 (0.2) 
117 
0.7 (0.2) 
118 
0 (0 to 0.1) Mean: 0 (0 to 
0) 
.85 
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Secondary Analysis Probiot
ic 
(n=155) 
Placebo 
(n=155) 
Absolute 
difference, 
95% CI 
Adjusted 
difference, 
95% CI† 
p-value 
Second follow-up 
ICECAP-O value¶ 
         
  Self-report, mean (SD) 
N 
0.7 (0.3) 
35 
0.7 (0.2) 
27 
0.1 (-0.1 to 
0.2) 
Mean: -0.1 (-
0.2 to 0) 
.15 
  Proxy, mean (SD) N 0.7 (0.2) 
84 
0.7 (0.2) 
90 
0 (-0.1 to 
0.1) 
Mean: 0 (-0.1 
to 0) 
.69 
Ever been hospitalized, 
n/N (%) 
42/152 
(27.6) 
36/153 
(23.5) 
0 (-0.1 to 
0.1) 
OR: 1.3 (0.7 
to 2.1) 
.41 
Death, n (%) 33 
(21.3) 
32 (20.6) 0 (-0.1 to 
0.1) 
OR: 1.0 (0.6 
to 1.8) 
.90 
Number of hospital 
stays, mean (SD) N 
0.4 (0.7) 
152 
0.3 (0.6) 
153 
0.1 (-0.1 to 
0.2) 
IRR: 1.2 (0.7 
to 1.9) 
.53 
Cumulative number of 
hospital days, mean (SD) 
N 
4.5 
(12.5) 
152 
5.4 (19.4) 
153 
0.9 (-2.8 to 
4.6) 
IRR: 1.0 
(0.43 to 2.29) 
1.00 
Incidence of antibiotic-
associated diarrhea, 
mean (SD) N 
0.8 (2.0) 
152 
0.6 (1.8) 
153 
0.2 (-0.2 to 
0.5) 
IRR: 1.4 (0.8 
to 2.5) 
.25 
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Secondary Analysis Probiot
ic 
(n=155) 
Placebo 
(n=155) 
Absolute 
difference, 
95% CI 
Adjusted 
difference, 
95% CI† 
p-value 
Cumulative days of 
antibiotic-associated 
diarrhea, mean (SD) N 
6.8 
(22.3) 
152 
4.4 (16.1) 
153 
2.4 (-2.0 to 
6.7) 
IRR: 1.8 (1.0 
to 3.5) 
.07 
Incidence of all-cause 
diarrhea, mean (SD) N 
1.8 (3.9) 
152 
1.6 (3.5) 
153 
0.2 (-0.6 to 
1.1) 
IRR: 1.1 (0.7 
to 1.6) 
.80 
Cumulative days of all-
cause diarrhea, mean 
(SD) N 
4.4 
(10.2) 
152 
4.4 (10.8) 
153 
0 (-2.3 to 
2.4) 
IRR: 1.2 
(0.78 to 2.0)  
.39 
At least one all-cause 
diarrhea, n/N (%) 
64/152 
(42.1) 
61/153 
(39.9) 
0 (-0.1 to 
0.1) 
OR: 1.0 (0.6 
to 1.8) 
.89 
Mean duration of 
diarrhea episodes for 
those with at least one 
diarrhea, mean (SD) N 
1.4 (0.6) 
64 
1.4 (0.6) 
61 
0.1 (-0.1 to 
0.3) 
Mean: 0.1 (-
0.1 to 0.2) 
.27 
*Self-report EQ-5D-5L and ICECAP – O completed by participants who had capacity. Proxy 711 
EQ-5D-5L and ICECAP – O completed by relatives on behalf of participants 712 
†Mean: Adjusted mean difference; OR: Adjusted odds ratio; IRR: Adjusted incidence rate 713 
ratio 714 
‡EQ-5D index values can range from -0.594 to 1, with a higher score indicating better health 715 
utility 716 
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§EQ-5D health status can range from 0 to 100, with a higher score indicating better overall 717 
health 718 
‖Transformed outcome (power of 2) 719 
¶ICECAP-O score can range from 0 to 1, with a higher score indicating higher capability 720 
 721 
 722 
 723 
 724 
